Eli Lilly and Company has announced that the Committee for Medicinal Products for Human Use (CHMP) has expressed a positive opinion in recommending the approval of Zypadhera (olanzapine long-acting injection) for maintenance treatment of schizophrenia in adult patients. The stand taken by the CHMP will have to be confirmed by the European Commission for the new indication to be considered as approved. The CHMP formed its opinion on the basis of data derived from eight studies, involving 2,054 patients.